Business Context and Reporting Period
This Form 8-K Current Report was filed by PharmAthene, Inc. on June 10, 2011. The filing discloses the entry into a material definitive agreement regarding a registered offering of common stock and warrants. The company is incorporated in Delaware and maintains its principal executive offices in Annapolis, Maryland.
Key Financial Metrics and Transaction Details
- Offering Size: 1,857,143 Units sold to accredited investors.
- Price per Unit: $3.50.
- Unit Composition: One share of common stock and one warrant to purchase 0.2 of a share.
- Gross Proceeds: Approximately $6.5 million (calculated as 1,857,143 units x $3.50).
- Net Proceeds: Approximately $5,765,000 after placement agent fees and offering expenses.
- Placement Agent Fees: 7.0% of gross proceeds.
- Expense Reimbursement: Up to $85,000 for transaction-related expenses.
- Warrant Terms: Exercisable immediately at $3.50 per share; expires on the fifth anniversary of issuance.
Material Changes and Unusual Items
The filing reports a significant capital raise event rather than operational performance changes. The company entered into Subscription Agreements with certain accredited investors and a Placement Agency Agreement with Leerink Swann LLC and Noble Financial Capital Markets. The offering is structured as a shelf takedown from a registration statement declared effective on February 12, 2009. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the current period versus prior periods.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard transactional representations. The company noted that the Placement Agency Agreement includes a right of first refusal for Leerink Swann LLC to provide certain future services. Investors are directed to the Prospectus Supplement and other SEC filings for comprehensive factual information regarding the company's current state of affairs.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds received, as the $5,765,000 figure is an estimate.
- Confirm the dilution impact of the 1,857,143 new shares and the potential future dilution from the 371,429 warrants (0.2 per unit).
- Review the full Prospectus Supplement for details on the use of proceeds and any specific covenants in the Subscription Agreements.
- Check subsequent filings to confirm if the expense reimbursement cap of $85,000 was fully utilized.